SHARE

J&J to sell its remaining 9.5% stake in Kenvue

Johnson & Johnson has said that it is planning to exit Kenvue, the consumer health business it spun out in 2022. The sale could be worth about $3.75bn, according to reports. J&J is focusing on its pharmaceutical and medical devises business.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.